Electrocardiography continues to serve as a foundational technique in cardiovascular research, yet electrode placement errors remain a persistent source of data quality issues across clinical and ...
HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...
SANTA CLARA, Calif.--(BUSINESS WIRE)-- HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced it ...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
Company engaging in multiple options for a constructive resolution Strategy is underpinned by a clinical study that achieved the agreed upon endpoints Company believes that labeling modifications can ...
HeartBeam (NASDAQ: BEAT), a medical-technology company developing advanced electrocardiogram solutions, was featured in a recent article that discussed its recognition as a Global IP and Technology ...
DiaCardia, a novel artificial intelligence model that can accurately identify individuals with prediabetes using either ...
Worldwide, over 300 million electrocardiograms (EKGs) are performed each year, with one-third of those taking place in the United States. Despite being so widely used, the technology of EKGs has been ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results